LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

C-Reactive Protein Point-Of-Care Test Evaluated

By LabMedica International staff writers
Posted on 27 Aug 2019
Image: The cobas b 101 POC system; an in vitro diagnostic (IVD) test system offering C-reactive protein, HbA1c and a complete lipid profile (CHOL, HDL, LDL, TG) on one device at the point of care (Photo courtesy of Roche Diagnostics).
Image: The cobas b 101 POC system; an in vitro diagnostic (IVD) test system offering C-reactive protein, HbA1c and a complete lipid profile (CHOL, HDL, LDL, TG) on one device at the point of care (Photo courtesy of Roche Diagnostics).
C-reactive protein (CRP) is a key mediator of the acute-phase response, with blood levels of CRP increasing rapidly after an inflammatory stimulus. Therefore, changes in serum levels of CRP are a clinically useful marker of infection, inflammation, and tissue injury.

CRP testing in the primary setting as in point-of-care (POC) can help reduce diagnostic uncertainty by differentiating between bacterial and viral infections and has been shown to be cost-effective for reducing inappropriate antibiotic prescriptions. However, despite the availability of POC devices, POC CRP testing has not yet been widely adopted in primary care clinics.

Clinical laboratory scientists at the Catharina Hospital and Technical University Eindhoven (Eindhoven, The Netherland) and their colleagues evaluated a POC CPR test at three sites and one reference laboratory. Within-run (repeatability), within-laboratory (intermediate precision), and between-laboratory precision (reproducibility) were assessed. Method comparison and matrix/lot-to-lot comparison studies were conducted using prospectively collected blood samples from 217 adults (apparently healthy or with clinically relevant conditions).

The investigators compared the analytical performance of the cobas b 101 POC system, which provides glycated hemoglobin (HbA1c) and lipid panel tests (measurement of cholesterol, triglyceride, and high-density lipoprotein; calculation of low-density lipoprotein) for managing diabetes and dyslipidemia at point-of-need. This method was compared with a reference test: CRPNX reagent on a Roche cobas c 501 module.

The scientists reported that clinically relevant CRP concentrations measured with the CRP Test showed good agreement with those measured by CRPNX reagent. Coefficients of variation (CV) for repeatability and intermediate precision ranged from 1.7%–4.0% and 1.9%–4.5%, respectively, for human serum pools containing CRP 4.7–350.7 mg/L; repeatability in clinical samples ranged from 1.6%–5.9% (3.3–360.3 mg/L). CVs for reproducibility ranged from 2.5%–4.0% (4.7–344.3 mg/L). CRP concentrations were comparable for capillary whole blood, serum, Li-heparin whole blood/plasma, K2 and K3 EDTA whole blood/plasma. The overall mean usability score was 4.18/5 and the error rate across 9,378 tests was 1.00%.

The authors concluded that their findings indicate that healthcare professionals can obtain precise and reproducible CRP values with the cobas POC CRP Test that show very good correlation with laboratory measurements. Importantly, operators considered the system convenient for use in the POC environment. The study was published in the September 2019 issue of the journal Clinical Biochemistry.

Related Links:
Catharina Hospital and Technical University Eindhoven

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more